Secondary Logo

Institutional members access full text with Ovid®

PIK3CA mutations in vascular malformations

Castillo, Sandra D.a; Baselga, Eulaliab; Graupera, Marionaa,c

Current Opinion in Hematology: May 2019 - Volume 26 - Issue 3 - p 170–178
doi: 10.1097/MOH.0000000000000496
VASCULAR BIOLOGY: Edited by M. Luisa Iruela-Arispe
Buy

Purpose of review Recently, it has been discovered that a subset of vascular malformations, of the lymphatic and venous type, are caused by oncogenic mutations in the PIK3CA gene. Now, efforts have been focused in the understanding of the molecular and cellular consequences of these mutations and the opportunities for novel-targeted therapies for these diseases.

Recent findings Here, we review the latest findings in the biology of oncogenic PIK3CA mutations in the pathogenesis of vascular malformations. We focus on the recent development of in-vitro and in-vivo tools for the study of PIK3CA-mutant vascular malformations with special interest in preclinical models for drug testing. Also, we review the latest advances in phosphoinositide 3-kinase (PI3K) inhibitors in the clinic and their repurposing for the treatment of lymphatic malformations and venous malformations.

Summary Oncogenic mutations on PIK3CA causing lymphatic malformations and venous malformations are also frequently found in epithelial cancer. Thus, fundamental research done in the cancer field during the past decades might be applied to the understanding of lymphatic malformations and venous malformations. Likewise, repurposing PI3K pathway inhibitors that are currently in cancer clinical trials can be used as a novel strategy for the treatment of these diseases. Here, we also open a debate for the consideration of lymphatic malformations and venous malformations as developmental tumours.

aVascular Signalling Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)

bHospital de la Santa Creu i Sant Pau, Barcelona

cCIBERONC, Instituto de Salud Carlos III, Madrid, Spain

Correspondence to Sandra D. Castillo, Vascular Signalling Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda Gran Via 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail: scastillo@idibell.cat

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.